Incyte (INCY) Gains from Investment Securities (2010 - 2026)
Incyte (INCY) reported Gains from Investment Securities of $572000.0 for Q1 2026, up 110.81% on a YoY basis from $271336.0 in Q1 2025, and up 356.5% quarter-over-quarter from -$223000.0 in Q4 2025.
Incyte (INCY) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Incyte has reported Gains from Investment Securities for 17 years, with the latest figure at $572000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 110.81% year-over-year to $572000.0; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (up 104.13% YoY), and the FY2025 full-year result was $3.2 million, down 84.03% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $572000.0, up from -$223000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $23.4 million in Q3 2024, with the low at -$283.1 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged -$13.5 million across 5 years, with a median of $794000.0 in 2022.
- The largest YoY upside for Gains from Investment Securities was 5595.31% in 2024 against a maximum downside of 1979.78% in 2024.
- Incyte's Gains from Investment Securities stood at $794000.0 in 2022, then soared by 1796.47% to $15.1 million in 2023, then slumped by 1979.78% to -$283.1 million in 2024, then surged by 99.92% to -$223000.0 in 2025, then surged by 356.5% to $572000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $572000.0 (Q1 2026), -$223000.0 (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 572,000.00 |
| Mar 31, 2026 | 572,000.00 |
| Dec 31, 2025 | -223,000.00 |
| Dec 31, 2025 | -223,000.00 |
| Sep 30, 2025 | -12.20 Mn |
| Sep 30, 2025 | -12.20 Mn |
| Jun 30, 2025 | 22.76 Mn |
| Jun 30, 2025 | 22.76 Mn |
| Mar 31, 2025 | -5.29 Mn |
| Mar 31, 2025 | -5.29 Mn |
| Dec 31, 2024 | -283.06 Mn |
| Dec 31, 2024 | -283.06 Mn |
| Sep 30, 2024 | 23.41 Mn |
| Sep 30, 2024 | 23.41 Mn |
| Jun 30, 2024 | 893,000.00 |
| Jun 30, 2024 | 893,000.00 |
| Mar 31, 2024 | 6.17 Mn |
| Mar 31, 2024 | 6.17 Mn |
| Dec 31, 2023 | 15.06 Mn |
| Dec 31, 2023 | 15.06 Mn |